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There was no significant difference in GORD(p=0.305), rhi-
nosinus disease(p=0.388) or oral corticosteroid requirement
(p=0.6896). Asthma Control Questionnaire (ACQ) was signifi-
cantly higher in OSA 3.3±1.3 compared to the no-OSA group
2.8±1.3, p=0.022 (Apnoea Hypoxia Index (AHI) 10)
Conclusion Asthmatics with co-morbid OSA are more likely to
have poor asthma control with significantly higher ACQ
scores. Additionally, these patients have significantly higher
rates of diabetes, dyslipidaemia and hypertension. Routine
screening for OSA and metabolic syndrome (“syndrome z”) is
recommended in asthmatics.
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Introduction and Objectives Existing HRQoL scales have poor
content validity for severe asthma as they fail to measure the
qualitatively different burdens experienced by the severe
asthma population compared to those with mild or moderate
asthma, in particular, the side effects of oral corticosteroids
(OCS). A new severe asthma quality of life questionnaire
(SAQ) has been designed using extensive patient input in qual-
itative studies as per FDA guidelines. The questionnaire has
16 questions rated on a 1–7 Likert scale and a 100 point
global quality of life scale (GQoL) similar to the EQ-5Ds 100
point visual analogue scale (VAS) (SAQ.org.uk).
Methods Consecutive consenting patients attending the severe
asthma clinic in Plymouth with severe asthma were invited to
participate in a cross sectional survey. Patients completed four
questionnaires the SAQ, mini Asthma Quality of Life Ques-
tionnaire (miniAQLQ), Asthma Control Test (ACT) and the
EQ-5D. Prednisolone dose and frequency of severe exacerba-
tions were obtained from clinic records.
Results 102 participants (64 female, mean age=51 years range
18–79 years), of whom 38 were on maintenance OCS con-
sented to take part, mean FEV1% of 69%. Correlations
between the four questionnaires were all above 0.65. Correla-
tions with frequency of severe exacerbations were SAQ 0.31,
miniAQLQ 0.31, ACT 0.34. The SAQ’s GQoL correlated
with the EQ-5D’s VAS at 0.73. The SAQ was significantly
better than the miniAQLQ at predicting the quality of life of
patients taking 10 mg OCS a day (p<0.05 vs p=0.88).
These questionnaires had parallel Results for doses up to
10 mg but above that only SAQ provided differentiation
between patients.
Conclusions Preliminary Results indicate that the SAQ may be
a more valid measure of quality of life in severe asthma than
existing questionnaires. The SAQ maps onto a pre-existing
health economic measure, the EQ-5D. Furthermore the SAQ
has greater sensitivity to differences in OCS dose compared to
the AQLQ. The SAQ will be assessed further in a larger vali-
dation study.
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The Improving Asthma Care Together (ImpACT) project
implements a novel model of care which provides an inte-
grated responsive services for asthma patients in Derby.
Aim The hypothesis of this project was that rapid review by a
specialist asthma nurse in the community during an asthma
exacerbation, would result in an improvement in patient’s
asthma control and their ability to self-manage their asthma.
Methods Four specialist asthma nurses were recruited to pro-
vide seven day cover for the service. Patients who reported
increasing asthma symptoms could access the service by self-
referral or referral from a healthcare professional. The inter-
vention involved a face-to-face review or a telephone call
from a specialist asthma nurse. Patients were offered a 30 min
face to face review at a variety of GP locations in the region.
A template for each ImpACT review was constructed and a
management plan issued at each consultation. A questionnaire
was devised and patients were asked to complete this approxi-
mately 6 weeks following the intervention. A 10 point scale
was used to ask patient’s what their confidence levels were in
self-managing their asthma (0=no confidence and 10=highly
confident) and how they rated their asthma control (0=poor
and 10=excellent).
Results This project commenced in January 2017. Between the
start date and June 2017 a total of 884 patients were
reviewed as part of the service. 397 face-to- face visits, 470
telephone consultations and 17 home visits. Patient’s self-rating
of their asthma control significantly improved following the
intervention (pre-intervention mean 3.4, standard deviation
[SD] 2.2 versus post-intervention mean 8.1 [SD 1.4]; paired t-
test <0.001; n=23). Patient’s self-reported confidence in
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